Discontinued — last reported Q3 '23
West Pharmaceutical Services Long-Term Debt - Fair Value decreased by 0.1% to $202.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.5%, from $201.20M to $202.20M. Over 2 years (FY 2023 to FY 2025), Long-Term Debt - Fair Value shows relatively stable performance with a -0.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A fair value lower than the carrying amount often indicates rising market interest rates or a change in credit risk.
The estimated market value of the company's long-term debt obligations if they were to be traded or settled in the curre...
Required disclosure that helps investors assess the sensitivity of debt to interest rate changes.
long_term_debt_fair_value| Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $204.40M | $203.00M | $201.60M | $200.50M | $201.20M | $201.90M | $202.10M | $202.40M | $202.20M |
| QoQ Change | — | -0.7% | -0.7% | -0.5% | +0.3% | +0.3% | +0.1% | +0.1% | -0.1% |
| YoY Change | — | — | — | -1.9% | — | -0.5% | +0.2% | +0.9% | +0.5% |